JPY 103.0
(-1.9%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 645.5 Million JPY | 242.26% |
2022 | 188.6 Million JPY | -63.73% |
2021 | 519.92 Million JPY | 641.07% |
2020 | 70.15 Million JPY | 362.52% |
2019 | 15.16 Million JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 547.46 Million JPY | -15.19% |
2024 Q2 | 296.94 Million JPY | -45.76% |
2023 FY | 645.5 Million JPY | 242.26% |
2023 Q3 | 200.61 Million JPY | -37.92% |
2023 Q1 | 245.65 Million JPY | 74.22% |
2023 Q4 | 645.5 Million JPY | 221.76% |
2023 Q2 | 323.16 Million JPY | 31.55% |
2022 Q3 | 602.56 Million JPY | 0.0% |
2022 Q4 | 141 Million JPY | -76.6% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 97.417% |
Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.992% |
Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 99.914% |
Shionogi & Co., Ltd. | 164.35 Billion JPY | 99.607% |
Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | 80.987% |
Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 98.494% |
Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 97.684% |
Eisai Co., Ltd. | 494.82 Billion JPY | 99.87% |
Morishita Jintan Co., Ltd. | 5.04 Billion JPY | 87.192% |
Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 98.954% |
Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 97.906% |
Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 98.378% |
Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 97.923% |
Tsumura & Co. | 132.88 Billion JPY | 99.514% |
Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 98.378% |
Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 95.145% |
Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 99.765% |
Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 98.538% |
Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 99.087% |
KYORIN Holdings, Inc. | 46.89 Billion JPY | 98.623% |
Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | 90.782% |
Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 97.463% |
SymBio Pharmaceuticals Limited | 8.14 Billion JPY | 92.072% |
MedRx Co., Ltd | 129 Million JPY | -400.39% |
Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | 80.275% |
Solasia Pharma K.K. | 673 Million JPY | 4.086% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 97.943% |
Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 99.606% |
Cyfuse Biomedical K.K. | 1.01 Billion JPY | 36.173% |
Toho Holdings Co., Ltd. | 523.98 Billion JPY | 99.877% |
Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | 90.715% |